ISSN: 1935-1232 (P)

ISSN: 1941-2010 (E)


Research Article - Clinical Schizophrenia & Related Psychoses ( 2021) Volume 0, Issue 0

Haneen A.R Aburamadan1, Sathvik Belagodu Sridhar1*, Talaat Matar Tadross2 and Atiqulla Shariff1
1Department of Clinical Pharmacy and Pharmacology, RAK Medical and Health Sciences University, Ras Al-Khaimah, United Arab Emirates
2Departmnent of Psychiatry, Ibrahim Bin Hamad Obaidallah Hospital, Ras Al-Khaimah, United Arab Emirates
*Corresponding Author:
Sathvik Belagodu Sridhar, Department of Clinical Pharmacy and Pharmacology, RAKCOPS, RAKMHSU, Ras Al-Khaimah, UAE, Tel: +971 971072043000, Email:

Received: 09-Jul-2021 Accepted Date: Jul 23, 2021 ; Published: 30-Jul-2021


Background: Analysis and evaluation of the prescribing pattern can improve clinical outcomes. There is a lack of available data regarding antipsychotic prescribing patterns in psychiatric in-patients in the United Arab Emirates.

Aim: This study aimed to assess the prescription pattern of antipsychotic medications in a psychiatry in-patient setting of a secondary care hospital in the UAE.

Methods: This prospective, observational study included psychiatric in-patients receiving antipsychotic therapy. We assessed the type, dose, route of administration, monotherapy, and combination therapy of antipsychotics used.

Results: One hundred and seventy patients were enrolled in the study. Bipolar I Disorder was diagnosed in the majority of the cases (21.8%), followed by schizophrenia (17.1%) and substance use disorder (10.6%). The most frequently prescribed antipsychotic drug was olanzapine (38.2%), followed by quetiapine (15.2%) and risperidone (8.8%). Olanzapine plus quetiapine (5.2%) and olanzapine plus risperidone (4.1) were the most prescribed combination therapy. Seven of the eleven antipsychotics used in our study had a PDD to DDD range of 0.7-1.3, which was considered adequate.

Conclusion: The study findings demonstrated a distinct prescription pattern for in-patients setting in RAK, UAE. The psychiatrist preferred to prescribe second-generation antipsychotic drugs over first-generation antipsychotic drugs.


Antipsychotic medications • Bipolar I disorder • Prescription pattern • Psychiatry in-patient department


Antipsychotics are a class of agents that can decrease psychotic symptoms in various psychiatric conditions. For severe psychiatric disorders such as schizophrenia and other psychoses, they are first-line pharmacological treatments. However, they are not commonly prescribed for other mental conditions, including depression; sleep disturbances, or obsessive-compulsive disorder [1]. The current availability of a wide range of antipsychotic agents makes a rational selection of antipsychotics a challenge. However, efficient the older typical antipsychotics are associated with unpleasant extrapyramidal side effects. Therefore, the introduction of newer antipsychotic medications has prompted significant changes in prescribing patterns in various mental illnesses [2]. The European countries report the vast difference in the prescribing rates for atypical antipsychotic drugs and typical antipsychotic drugs in the treatment of schizophrenia. The ratio is low in countries like France (20.2%), Germany (20.7%), and Italy (22.3%), while it is higher in Denmark (33.3%), the Netherlands (35.6%), and the UK (27.5%) [3].

Atypical antipsychotics (67.7%) were more often prescribed than typical antipsychotics in the Middle East, and the most frequently prescribed antipsychotics being risperidone and haloperidol [4]. Schizophrenic in-patients frequently received second-generation antipsychotics in combination therapy rather than the recommended monotherapy in doses that differed from the recommended guidelines. Risperidone was the most commonly prescribed drug [5]. Prescription patterns of antipsychotic drugs vary significantly across countries and also continents. This is attributed to variations in healthcare policy, medication supply and cost, psychiatric expertise, and treatment modalities [6].

Apart from these studies, there is a lack of available data regarding antipsychotic prescribing patterns in psychiatric in-patients in the United Arab Emirates. Therefore, this study attempts to comprehensively assess the prescribing pattern of antipsychotics in a secondary care hospital in the UAE. The type of antipsychotic drug, dose, routes of administration, duration of therapy, monotherapy and combination therapy, and maintenance therapy during hospitalization and upon discharge were assessed.

Materials and Methods

Study design and setting

This prospective observational study was conducted for seven months at the department of psychiatry in a secondary care government hospital of Ras Al Khaimah, United Arab Emirates.


Psychiatric in-patients of any age group and gender diagnosed with any psychiatric disorder and prescribed at least one antipsychotic medication (inclusion criteria) were enrolled in this study. Psychiatric in-patients who are not managed/prescribed with any antipsychotic medications readmitted patients for recurrences or relapses, and patients managed with antipsychotics but admitted in the other ward/specialties of the hospital were excluded from the study. This study was conducted after obtaining approval from both the institutional and local research and ethics committee of Ras Al Khaimah (RAK MHSU-REC: 8-2015-PG-P). All procedures performed in studies complied with the institutional and local research and ethics committee's standards.

Data collection

The principal investigator identified the cases by attending the ward rounds at the study site along with the treating psychiatrist. Thus, identified patients were enrolled in the study, and all the necessary and relevant data was collected through patients’ electronic medical records. Collected data were assessed according to the specified study parameters, including the type of drug, dose, and administration route, duration of therapy, monotherapy and combination therapy, and maintenance therapy during hospitalization and upon discharge.

Data analysis

The data was then compiled in a Microsoft® Excel sheet and evaluated with SPSS® version 24.0. The continuous data is represented as Mean Standard Deviation (MSD), while the categorical data are expressed as percentages. The prescription pattern of antipsychotics was expressed as Defined Daily Doses (DDD), Prescribed Daily Doses (PDD), and PDD ratio to DDD. DDD was obtained from the WHO collaborating center for drug statistics methodology. Simultaneously, PDD was mathematically measured by averaging the daily doses of the antipsychotics prescribed among the study population. Finally, the PDD to DDD ratio was determined by dividing the calculated PDD by the medication’s DDD.


The research was effective in enrolling a total of 170 patients who met the requirements for inclusion. Males made up the bulk of the participants in the sample (57.6%). The study population's age varied between 19 years to 73 years (Mean age: 34.88 ± 12.90 years). Other demographic parameters of the study population are presented in Table 1. The Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria were used to determine the psychiatric condition of the patients. A significant portion of the study patients were diagnosed with Bipolar I disorder (21.8%) (Table 2).

Demographic Parameters Mean ± SD (95% CI)
Age (in years) 34.88 + 12.90 (32.9-36.8)
Length of hospital stay (in days) 17.11 + 17.27 (14.5-19.7)
School education (in years) 9.43 ± 4.87 (8.6-10.1)
Demographic Parameters
  No. of patients (%)
Male 98 (57.6%)
      Female +72 (42.4%)
Local 78 (45.9%)
Expatriate 92 (54.1%)
Past medical history (General medical conditions)  
Present 53 (31.2%)
Absent 117 (68.8%)
Past medication history (Previous treatment with antipsychotics)  
Yes 84 (49.4%)
No 63 (37.1%)
Unknown 23 (13.5%)
Previous treatment with other  psychotropics  
Yes 86 (50.6%)
No 60 (35.3%)
Unknown 24 (14.1%)
Family history of psychiatric illness  
Yes 21 (12.4%)
No 64 (37.6%)
Unknown 85 (50%)
Current employment status  
Employed 71 (41.8%)
Not employed 99 (58.2%)
Current marital status  
Single 74 (43.5%)
Married 85 (50%)
Divorced 11(6.5%)
Alcohol use  
Yes 29 (17.1%)
No 141 (82.9%)
Illicit Drug Use  
Yes 24 (14.1%)
No 146 (85.9%)
Tobacco use  
Yes 62 (36.5%)
No 108 (63.5%)
Number of suicidal attempts (current or previous)  
None 143 (84.1%)
One or more 27 (15.9%)

Table 1: Patient demographics.

Diagnosis ICD-10 Code No. of patients (%)
Bipolar I Disorder F06.31 37 (21.8)
Schizophrenia F20.9 29 (17.1)
Substance Use Disorder F19 18 (10.6)
Schizoaffective Disorder F25.9 17 (10)
Adjustment Disorder F43.2 11 (6.5)
Alcohol Use Disorder F10 10 (5.9)
Major Depressive Disorder F32.9 9 (5.3)
Unspecified Schizophrenia Spectrum and Other Psychotic Disorder F23.9 7 (4.1)
Major Depressive Disorder with psychotic features F33.3 7 (4.1)
Borderline Personality Disorder F60.31 4 (2.4)
Brief Psychotic Disorder F23.0 3 (1.8)
Intellectual Disability F78 3 (1.8)
Schizophreniform Disorder F20.8 2 (1.2)
Other Specified Schizophrenia Spectrum and Other Psychotic Disorder F23.8 2 (1.2)
Delusional Disorder F22.0 2 (1.2)
Conduct Disorder F91.9 2 (1.2)
Psychotic Disorder due to another Medical Condition F28 1 (0.6)
Substance/Medication-Induced Psychotic Disorder F1x.5 1 (0.6)
Antisocial Personality Disorder F60.2 1 (0.6)
Personality Change Due to another Medical Condition F62.8 1 (0.6)
Conversion Disorder F44.0 1 (0.6)
Dissociative Amnesia F44.0 1 (0.6)
Obsessive-Compulsive Disorder F42.9 1 (0.6)

Table 2: Medical diagnosis of the study patients.

Prescription pattern of antipsychotics

A total of eleven antipsychotics (either as mono or polytherapy or as depot preparations) were prescribed for 170 patients (1.32 ± 0.43 antipsychotics prescribed/patient). The majority of the study patients (68.8%) received Second-Generation Antipsychotics (SGAs) as monotherapy. Risperidone depot preparation was the most common (14 out of 15 patients) depot preparation used among the study population (Table 3). The Prescribed Daily Doses (PDD), Defined Daily Doses (DDD), and PDD ratio to DDD for all the antipsychotics prescribed are presented in Table 4. We observed that seven out of eleven antipsychotics used in our study were within the adequate PDD to DDD ratio between 0.7-1.3. All antipsychotics used as maintenance therapy during hospitalization were administered orally except for depot preparations, administered through deep intramuscular Injection. We further attempted to correlate the antipsychotics prescribed during hospitalization to the different psychiatric diagnoses in this study. The correlations are compiled in Table 5.

Type of antipsychotic/s No. of patients (%)
One FGA 7 (4.1)
Haloperidol 4 (2.35)
Chlorpromazine 2 (1.17)
Prochlorperazine 1 (0.58)
Two FGAs 1 (0.58)
Haloperidol+Chlorpromazine 1 (0.58)
One SGA 117 (68.8)
Olanzapine 65 (38.23)
Quetiapine 26 (15.29)
Risperidone 15 (8.82)
Aripiprazole 9 (5.29)
Ziprasidone 1 (0.58)
Sertindole 1 (0.58)
Two SGAs 24 (14.1)
Olanzapine+Quetiapine 9 (5.29)
Olanzapine+Risperidone 7 (4.1)
Olanzapine+Aripiprazole 2 (1.1)
Risperidone+Quetiapine 2 (1.1)
Quetiapine+Aripiprazole 2 (1.1)
Quetiapine _Sertindole 1 (0.58)
Quetiapine+Clozapine 1 (0.58)
Three SGAs 1 (0.58)
Olanzapine+Quetiapine+Aripiprazole 1 (0.58)
One FGA+one SGA 5 (2.94)
Chlorpromazine+Quetiapine 1 (0.58)
Chlorpromazine+Risperidone 1 (0.58)
Haloperidol+Quetiapine 3 (1.76)
Two FGAs+1 Depot preparation 1 (0.58)
Chlorpromazine+Trifluoperazine+Haloperidol depot 1 (0.58)
One SGA+1 Depot preparation 7 (4.1)
Olanzapine+Risperidone depot 4 (2.3)
Risperidone+Risperidone depot 2 (1.1)
Quetiapine+Risperidone depot 1 (0.58)
Two SGAs+1 Depot preparation 6 (3.52)
Risperidone+Quetiapine+Risperidone depot 3 (1.76)
Risperidone+Olanzapine+Risperidone depot 2 (1.1)
Quetiapine+Aripiprazole+Risperidone depot 1 (0.58)
One FGA+One SGA+1 Depot preparation 1 (0.58)
Haloperidol+Quetiapine+Risperidone depot 1 (0.58)
Total 170 (100)

Table 3: Antipsychotics used as mono/polytherapy during hospitalization.

Type of antipsychotic/s No. of patients (%) ATC Code PDD (mg) DDD (mg) PDD/DDD
First generation antipsychotics
Haloperidol 9 (5.2) N05AD01 7.7 8 0.96
Chlorpromazine 6 (3.5) N05AA01  154.1 300 0.51
Prochlorperazine 1 (0.58) N05AB04 20 100 0.2
Trifluoperazine 1 (0.58) N05AB06  10 20 0.5
Second generation antipsychotics
Olanzapine 90 (52.9) N05AH03  12.2 10 1.22
Quetiapine 52 (30.5) N05AH04 294.2 400 0.73
Risperidone 32 (18.8) N05AX08 4.3 5 0.86
Aripiprazole 15 (8.8) N05AX12  16 15 1.06
Ziprasidone 1 (0.58) N05AE04 160 80 2
Sertindole 2 (1.17) N05AE03 18 16 1.12
Clozapine 1 (0.58) N05AH02  400 300 1.33
Depot antipsychotic preparations
Risperidone depot 14 (8.2) N05AX08  6.3 2.7 2.33
Haloperidol depot 1 (0.58) N05AD01 3.3 3.3 1

Table 4: PDD, DDD values, and PDD/DDD ratio for the antipsychotics used as in the study population.

Disease / drug O R Q A Z H S Cl P Ch T
Bipolar i disorder 27 1 6 4 0 1 1 0 0 0 0
Schizophrenia 14 10 9 5 1 1 1 1 0 1 1
Substance use disorder 5 0 15 0 0 0 0 0 0 1 0
Schizoaffective disorder 9 8 2 3 0 0 0 0 0 0 0
Adjustment disorder 9 1 2 1 0 0 0 0 0 0 0
Alcohol use disorder 3 1 6 0 0 4 0 0 0 1 0
Major depressive disorder 2 3 3 1 0 0 0 0 0 0 0
Unspecified schizophrenia spectrum and other psychotic disorder 5 1 0 0 0 2 0 0 0 1 0
Major depressive disorder with psychotic features 3 1 2 1 0 0 0 0 0 0 0
Borderline personality disorder 2 0 1 0 0 0 0 0 1 0 0
Brief psychotic disorder 2 1 1 0 0 0 0 0 0 0 0
Intellectual disability 1 1 0 0 0 1 0 0 0 0 0
Schizophreniform disorder 1 2 0 0 0 0 0 0 0 0 0
Other specified schizophrenia spectrum and other psychotic disorder 1 1 0 0 0 0 0 0 0 0 0
Delusional disorder 2 0 1 0 0 0 0 0 0 0 0
Conduct disorder 0 0 2 0 0 0 0 0 0 1 0
Psychotic disorder due to another medical condition 0 1 0 0 0 0 0 0 0 0 0
Substance/medication-induced psychotic disorder 1 0 0 0 0 0 0 0 0 0 0
Antisocial personality disorder 0 0 0 0 0 0 0 0 0 1 0
Personality change due to another medical condition 0 0 1 0 0 0 0 0 0 0 0
Conversion disorder 1 0 1 0 0 0 0 0 0 0 0
Dissociative amnesia 1 0 0 0 0 0 0 0 0 0 0
Obsessive-compulsive disorder 1 0 0 0 0 0 0 0 0 0 0

Table 5: Correlation of commonly prescribed antipsychotics and psychiatric diagnosis.

Management of acute psychotic agitation using parenteral antipsychotics, sedatives, and hypnotics

In patients with acute psychotic agitation, first-generation parenteral antipsychotics were administered intramuscularly when required, and 34.1% of these patients were managed with chlorpromazine injection. Among the parenteral sedatives and hypnotics, diazepam was prescribed for 23.5% of patients with acute psychotic agitation (Table 6). Parenteral diazepam and midazolam were administered intravenously, while parenteral promethazine was administered intramuscularly.

Type of medication Dose (in mg) No. of patients (%)
Parenteral FGA
Chlorpromazine 58 (34.1)
  25 4 (2.4)
  50 54 (31.8)
Haloperidol 30 (17.6)
  2.5 1 (0.6)
  5 23 (13.5)
  10 6 (3.5)
Zuclopenthixol 50 3 (1.8)
Parenteral sedatives and hypnotics
Diazepam 40 (23.5)
  2.5 1 (0.6)
  3 2 (1.2)
  5 18 (10.6)
  10 19 (11.2)
Promethazine 2 (1.2)
  25 1 (0.6)
  50 1 (0.6)
Midazolam 3 1 (0.6)

Table 6: Medications used for management of acute psychotic agitation.

Psychotropic co-medications

Mood stabilizers (75, 44.1%), sedatives and anxiolytics (60, 35.3%), and antidepressants (52, 30.6%) were the most frequently administered psychotropic co-medications. Anticholinergics were prescribed in 26 (15.3%) of the patients. In 20 (11.8%) of the patients, other drugs (antiepileptics or anti-dementia) were prescribed.


In our study, most of the study populations were diagnosed to have Bipolar I disorder, followed by schizophrenia. The prevalence of these diseases was similar to the general prevalence [7]. A clear family history of psychiatric disorders was observed only in 12.4% of the study patients. Those with a family history of all mental illnesses (except substance abuse) and a suicidal history are at a significantly greater risk of developing schizophrenia [8]. The mean length of hospitalization in our study was 17.11 ± 17.27 days. In our study, Bipolar I disorder was the most common psychiatric diagnosis for which antipsychotics were prescribed, followed by schizophrenia and substance abuse disorder. Two previous reports suggest that antipsychotics were the most commonly prescribed in schizophrenia, followed by psychotic disorder and substance use disorder [6,9]. A UK- based study also reported that SGA were commonly prescribed for Bipolar disorder without psychotic features, while FGA were prescribed for schizophrenia and Bipolar disorder with psychotic features [1].

The mean total number of drugs prescribed and antipsychotics prescribed in our study patients was 2.69 ± 1.09 and 1.23 ± 0.43 per patient, respectively. This is analogous to the study reported by Jyothi, where the average number of antipsychotic medications prescribed was 1.17 [10]. According to World Health Organization recommendations, the number of antipsychotic drugs/prescriptions should be within the 1.6–1.8/encounter [6], a standard that was confirmed in our study. Antipsychotic polytherapy is defined as when two or more antipsychotic drugs are prescribed concurrently [11]. In our study, 72.9% of patients received antipsychotics as monotherapy, while others were managed with antipsychotic polytherapy during hospitalization. This is in line with a Spanish study that reported antipsychotic monotherapy (69.2%) and polytherapy (21.8%) [12]. In contrast, a Middle-Eastern-based study involving the same psychiatric inpatient setting of our study revealed SGAs used commonly in combination therapy rather than in monotherapy [5]. This contradictory finding might be attributed to its multi-centric design and a small number of patients included from our psychiatric in-patient unit.

In our study, the most commonly prescribed combination therapy was olanzapine plus quetiapine (5.2%) and olanzapine plus risperidone (4.1%). The most widely used antipsychotic drug combination has been identified as olanzapine and risperidone in a study [12]. In the same study, polytherapy prevalence of three and four combinational antipsychotics were 1.5% and 0.3%, respectively [12]. However, in our study, polytherapy with three antipsychotics was less significant (0.6%).

Our study did not have polytherapy with four antipsychotics. A study with similar findings reported that most patients (53.3%) were managed with antipsychotic monotherapy compared to polytherapy 46.6% [6]. Contradictory findings where the antipsychotic combination was used more frequently than antipsychotic monotherapy are reported [2,13,14]. The discrepancies in the antipsychotic therapy might be related to psychiatrists’ preferences based on their clinical experience and awareness of different practice guidelines for prescribing antipsychotics [13].

A majority of our study patients (68.8%) received SGA, while a small percentage of study patients received conventional/first-generation antipsychotics. A similar finding was reported in an Indian study, wherein atypical antipsychotics (59%) were preferred over typical antipsychotics (28.6%) [7]. In contrast, some studies have reported FGA as the most commonly prescribed class of medications [2,13,15]. This discrepancy in prescribing practice may be due to the availability and cost of antipsychotic medications. Olanzapine was the most common antipsychotic prescribed in 52.9% of patients, followed by quetiapine (30.5%) and risperidone (18.8%). Concordance findings have been reported in a French study where olanzapine (70%) was the commonest prescribed antipsychotic, followed by risperidone (44.4%) [16]. As per a systematic review, olanzapine is more effective than other atypical antipsychotic drugs except for clozapine [17].

Among eleven antipsychotics used in our study population, three antipsychotics, namely prochlorperazine (PDD to DDD ratio 0.2), chlorpromazine, and trifluoperazine (PDD to DDD ratio 0.5 each), were used in inadequate doses, suggesting underutilization of these antipsychotics. Thakkar KB also observed underutilization of two antipsychotics, namely, chlorpromazine (PDD to DDD ratio 0.26) and lithium (PDD to DDD ratio 0.5) [15]. In a study conducted by Ranjan, similar findings were reported where levosulpride was used in sub-therapeutic doses as indicated by its PDD to DDD ratio of 0.18 [18]. In our study, ziprasidone and risperidone depot preparation were overly utilized (PDD to DDD ratio of 2 and 2.33, respectively). Similar observations were noted in a study where olanzapine and aripiprazole were overly utilized, as indicated by the PDD to DDD ratio of 2 [19]. In another study, Adesola AO reported a prevalence of high- dose antipsychotic prescribing in about 38% of their study population. They defined high-dose as a PDD to DDD ratio of more than 1.5 [20]. Balaji observed the PDD to DDD ratio of 5 for trifluoperazine, indicating overutilization of this antipsychotic [21].

In our study, parenteral anxiolytics were used to control psychotic agitation and conventional antipsychotics for sedation and agitation control. Parenteral Chlorpromazine (34.1%) and diazepam (23.5%) were the most often prescribed drugs in our study, which contradicts a report wherein parenteral haloperidol and promethazine were the most commonly used to control psychotic agitation [5]. Antipsychotics in depot injections were administered to only 8.8% of patients, where risperidone was the most commonly prescribed. Previous studies report a higher rate of prescribing depot antipsychotics within the group of typical antipsychotics [3,13]. Comparable findings can be reflected by a higher adherence to oral antipsychotics in our study patients.

Moreover, in a Finland study, the usage of depot antipsychotics was linked to a lower re-hospitalization rate than using oral formulations of the same drugs [22]. The NHS guidelines state that the use of depot antipsychotic preparation is determined by the level of adherence to oral medications. Furthermore, it recommends that depot antipsychotics be prescribed only to patients whose non-compliance is a primary medical concern in their treatment course [23].

Conformance with the international guidelines

Overall, the observed clinical practice regarding antipsychotic prescribing was in accordance with the treatment guidelines recommended by American Psychiatric Association (APA) and National Institute for Health and Care Excellence (NICE) [22,23].

Prescribing antipsychotics as monotherapy

The APA guidelines recommend using two or more antipsychotic medications concurrently should not be routinely prescribed [24]. In our study, most study patients (68.8%) received antipsychotics as monotherapy, while others were managed with an antipsychotic combination during hospitalization.

Prescription of depot antipsychotic preparation

The NICE recommends that antipsychotic depot injections be prescribed in patients with inadequate oral treatment compliance in the maintenance phase [22]. In our study, fifteen patients (8.8%) received antipsychotic depot injections where non-compliance was a primary medical concern.


Our study findings suggest that majority of psychiatric in-patients received antipsychotics as monotherapy. The most prominent condition was found to be bipolar I disorder, accompanied by schizophrenia. The most often prescribed antipsychotic medication was olanzapine. This research presents observational evidence of prescription patterns for antipsychotic drugs in the psychiatry in-patient setting. The clinicians had a preference for prescribing second-generation antipsychotics over first-generation antipsychotic drugs for various psychiatric illnesses. The study setting's current clinical practice was concordant with the international guidelines' recommendations where rational antipsychotic prescribing was effectively implemented.

Limitation of the Study

For some study patients, information on social and medical histories were not available in the electronic medical record.


Our sincere thanks to all the health care staff in the psychiatric study community and the hospital director for their kind support. The authors express their appreciation to all the RAK Medical and Health Sciences University administrators, Ras Al Khaimah, for their gracious support for the study period.

Conflict of Interest

The authors declare no conflict of interest.


Citation: Aburamadan, Haneen A.R, Sathvik Belagodu Sridhar, Talaat Matar Tadross and Atiqulla Shariff. “Assessment of Prescription Pattern of Antipsychotic Medications in a Psychiatry Inpatient Setting of a Secondary Care Hospital of United Arab Emirates.” Clin Schizophr Relat Psychoses 15S (2021). Doi:10.3371/CSRP.AHSS.073021.

Copyright: © 2021 Aburamadan HAR, et al. This is an open-access article distributed under the terms of the creative commons attribution license which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.